Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] closed the trading session at $13.07 on 2025-07-18. The day’s price range saw the stock hit a low of $8.0, while the highest price level was $18.0.
The stocks have a year to date performance of -96.89 percent and weekly performance of 252.29 percent. The stock has been moved at -85.09 percent over the last six months. The stock has performed 148.67 percent around the most recent 30 days and changed -74.83 percent over the most recent 3-months.
If compared to the average trading volume of 1.34M shares, CYCC reached to a volume of 22250567 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cyclacel Pharmaceuticals Inc [CYCC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYCC shares is $240.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYCC stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Cyclacel Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 18, 2022. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on April 27, 2020, representing the official price target for Cyclacel Pharmaceuticals Inc stock.
The Price to Book ratio for the last quarter was 3.69, with the Price to Cash per share for the same quarter was set at 2.18.
CYCC stock trade performance evaluation
Cyclacel Pharmaceuticals Inc [CYCC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 252.29. With this latest performance, CYCC shares gained by 148.67% in over the last four-week period, additionally sinking by -85.09% over the last 6 months – not to mention a drop of -85.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYCC stock in for the last two-week period is set at 57.35, with the RSI for the last a single of trading hit 3.59, and the three-weeks RSI is set at 3.87 for Cyclacel Pharmaceuticals Inc [CYCC]. The present Moving Average for the last 50 days of trading for this stock 17.27, while it was recorded at 9.03 for the last single week of trading, and 81.62 for the last 200 days.
Cyclacel Pharmaceuticals Inc [CYCC]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cyclacel Pharmaceuticals Inc [CYCC] shares currently have an operating margin of -96235.71% and a Gross Margin at 71.43%. Cyclacel Pharmaceuticals Inc’s Net Margin is presently recorded at -59607.14%.
Cyclacel Pharmaceuticals Inc (CYCC) Capital Structure & Debt Analysis
According to recent financial data for Cyclacel Pharmaceuticals Inc. ( CYCC), the Return on Equity (ROE) stands at -1949.77%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -168.60%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Cyclacel Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -271.74%, showcasing its effectiveness in deploying capital for earnings.
Cyclacel Pharmaceuticals Inc (CYCC) Efficiency & Liquidity Metrics
Based on Cyclacel Pharmaceuticals Inc’s (CYCC) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Cyclacel Pharmaceuticals Inc (CYCC) Efficiency & Liquidity Metrics
Cyclacel Pharmaceuticals Inc [CYCC]: Institutional Ownership
There are presently around $6.64%, or 17.24%% of CYCC stock, in the hands of institutional investors.
